Canopy Growth Corporation (CGC) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

It has experienced a hiccup, but the company is still on the right path. That’s the opinion of Roth MKM analyst Bill Kirk on ...

Canopy Growth's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Read why ...

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors. The post Should You Buy ...

In a report released on November 8, Lisa Lewandowski from Bank of America Securities reiterated a Sell rating on Canopy Growth (CGC – Research Report), with a price target of C$ ... dampen investor ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The company saw a huge decline in Canadian adult-use cannabis, with revenues down 24% at C$18.4 million from that category, offsetting the 16% gain from Canadian medical cannabis which reached C$18.7 ...

Canopy Growth Reports Second Quarter Fiscal Year 2025 Financial Results. Storz & Bickel net revenue increased 32% ...

Analysts estimate that Canopy Growth will report an earnings per share (EPS) of $-0.32. The announcement from Canopy Growth is eagerly anticipated, with investors seeking news of surpassing estimates ...

The price currently set on this stock reflects its superior financial health and position in the market. In addition, it may be less risky than Canopy Growth but remains susceptible to regulatory ...